[1] Disease GBD, Injury I, Prevalence C.Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390(10100): 1211-1259. [2] Ferlay J, Colombet M, Soerjomataram I, et al.Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. Int J Cancer, 2019, 144(8): 1941-1953. [3] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. [4] Pfister DG, Spencer S, Adelstein D, et al.Head and Neck Cancers, Version 2.2020[J]. J Natl Compr Canc Netw, 2020, 18(7): 873-898. [5] Cooper JS, Pajak TF, Forastiere AA, et al.Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck[J]. N Eng J Med, 2004, 350(19): 1937-1944. [6] Bernier J, Domenge C, Ozsahin M, et al.Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer[J]. N Eng J Med, 2004, 350(19): 1945-1952. [7] Sacco AG, Cohen EE.Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma[J]. J Clin Oncol, 2015, 33(29): 3305-3313. [8] Zhang L, Liu K, Han B, et al.The emerging role of follistatin under stresses and its implications in diseases[J]. Gene, 2018, 639: 111-116. [9] Morianos I, Papadopoulou G, Semitekolou M, Xanthou G.Activin-A in the regulation of immunity in health and disease[J]. J Autoimmun, 2019, 104: 102314. [10] Shi L, Resaul J, Owen S, et al.Clinical and Therapeutic Implications of Follistatin in Solid Tumours[J]. Cancer Genomics Proteomics, 2016, 13(6): 425-435. [11] Chang KP, Kao HK, Liang Y, et al.Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression[J]. Ann Surg Oncol, 2010, 17(7): 1945-1956. [12] Marini KD, Croucher DR, McCloy RA, et al. Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy [J]. Sci Transl Med, 2018, 10(451): eaat3504. [13] Li K, Zhang Z, Mei Y, et al.Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion via NF-kappaB inhibition[J]. Theranostics, 2021, 11(7): 3196-3212. [14] Yi Z, Wei S, Jin L, et al.KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway[J]. Cell Mol Gastroenterol Hepatol, 2022, 13(2): 643-667. [15] Chen YI, Chang CC, Hsu MF, et al.Homophilic ATP1A1 binding induces activin A secretion to promote EMT of tumor cells and myofibroblast activation[J]. Nat Commun, 2022, 13(1): 2945. [16] He BL, Yang N, Man CH, et al.Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia[J]. EMBO Mol Med, 2020, 12(4): e10895. [17] de Winter JP, ten Dijke P, de Vries CJ, et al. Follistatins neutralize activin bioactivity by inhibition of activin binding to its type Ⅱ receptors[J]. Mol Cell Endocrinol, 1996, 116(1):105-114. [18] Colak S, Ten Dijke P.Targeting TGF-beta Signaling in Cancer[J]. Trends Cancer, 2017, 3(1): 56-71. [19] Perk J, Iavarone A, Benezra R.Id family of helix-loop-helix proteins in cancer[J]. Nat Rev Cancer, 2005, 5(8): 603-614. [20] Norton JD.ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis[J]. J Cell Sci, 2000, 113( Pt 22): 3897-3905. [21] Huang YH, Hu J, Chen F, et al.ID1 Mediates Escape from TGFbeta Tumor Suppression in Pancreatic Cancer[J]. Cancer Discov, 2020, 10(1): 142-157. [22] Tang J, Gordon GM, Nickoloff BJ, Foreman KE.The helix-loop-helix protein id-1 delays onset of replicative senescence in human endothelial cells[J]. Lab Invest, 2002, 82(8): 1073-1079. [23] Suh HC, Leeanansaksiri W, Ji M, et al.Id1 immortalizes hematopoietic progenitors in vitro and promotes a myeloproliferative disease in vivo[J]. Oncogene, 2008, 27(42): 5612-5623. [24] Jin J, Wang H, Si J, et al.ZEB1-AS1 is associated with poor prognosis in non-small-cell lung cancer and influences cell migration and apoptosis by repressing ID1[J]. Clin Sci (Lond), 2019, 133(2): 381-392. [25] Lin J, Guan Z, Wang C, et al.Inhibitor of differentiation 1 contributes to head and neck squamous cell carcinoma survival via the NF-kappaB/survivin and phosphoinositide 3-kinase/Akt signaling pathways[J]. Clin Cancer Res, 2010, 16(1): 77-87. |